However, it is important to note that although EBUS-GS might be considered one of the sampling procedures to safely obtain tissues from PPLs for mutation analysis of NSCLC after EGFR-TKI treatment, the detection rate for malignant cells was significantly lower for peripherally located lesions, as shown in this study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.